Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Prevalence of Multi-drug Resistant Acinetobacter baumannii (MDRAB) in Amman Jordan During 2018

Author(s): Layla El-khatib, Saed Al-Dalain, Rama Al-Matarneh, Sara Al-Bustanji, Marwa Al-Dmour, Yara Al-Amarin and Yasser Gaber*

Volume 21, Issue 1, 2021

Published on: 11 December, 2019

Page: [105 - 111] Pages: 7

DOI: 10.2174/1871526519666191211144344

Price: $65

conference banner
Abstract

Purpose: Acinetobacter baumannii is an opportunistic pathogen, and is among the most problematic nosocomial infections as well as community-acquired infections. This retrospective study was conducted as an attempt to determine the prevalence of multidrug-resistant A. baumannii (MDRAB) isolates from the north and central Jordan area during 2018.

Methods: Patients’ records provided by an accredited central private laboratory located in Amman, were examined for A. baumannii isolates identified during this period. The isolates were identified to the species level using the API-10S system and the antimicrobial sensitivity testing was determined using the Kirby–Bauer disc diffusion method.

Results: A total of 43 unduplicated isolates were obtained and classified according to clinical sampling source into: Group I (blood), Group II (urine) and Group III (wound, pus, sputum, bedsore and others). Total MDRAB isolates recorded were 29 (67.4 %). Resistance to imipenem was found to be 36% and 94% among groups II and III, respectively, and resistance to meropenem was 60% and 88% among the same groups, respectively.

Conclusion: Antimicrobial stewardship programs at a national scale are needed to calculate the actual proportion of MDRAB in the country and to combat its increasing emergence and decrease the magnitude of antibiotic resistance.

Keywords: Acinetobacter, resistance, imipenem, tigecycline, kirby-bauer disk, Jordan.

Graphical Abstract

[1]
Joshi, S.G.; Litake, G.M. Acinetobacter baumannii: An emerging pathogenic threat to public health. World J. Clin. Infect. Dis., 2013, 3(3), 25-36.
[http://dx.doi.org/10.5495/wjcid.v3.i3.25]
[2]
Stahl, J.; Bergmann, H.; Göttig, S.; Ebersberger, I.; Averhoff, B. Acinetobacter baumannii virulence is mediated by the concerted action of three phospholipases D. PLoS One, 2015, 10(9)e0138360
[http://dx.doi.org/10.1371/journal.pone.0138360 ] [PMID: 26379240]
[3]
Dexter, C.; Murray, G.L.; Paulsen, I.T.; Peleg, A.Y. Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev. Anti Infect. Ther., 2015, 13(5), 567-573.
[http://dx.doi.org/10.1586/14787210.2015.1025055 ] [PMID: 25850806]
[4]
Weber, B.S.; Harding, C.M.; Feldman, M.F. Pathogenic Acinetobacter: from the cell surface to infinity and beyond. J. Bacteriol., 2015, 198(6), 880-887.
[http://dx.doi.org/10.1128/JB.00906-15 ] [PMID: 26712938]
[5]
Asif, M.; Alvi, I.A.; Rehman, S.U. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist., 2018, 11, 1249-1260.
[http://dx.doi.org/10.2147/IDR.S166750 ] [PMID: 30174448]
[6]
Lee, K.; Yong, D.; Jeong, S.H.; Chong, Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med. J., 2011, 52(6), 879-891.
[http://dx.doi.org/10.3349/ymj.2011.52.6.879 ] [PMID: 22028150]
[7]
Antunes, L.C.; Visca, P.; Towner, K.J. Acinetobacter baumannii: evolution of a global pathogen. Pathog. Dis., 2014, 71(3), 292-301.
[http://dx.doi.org/10.1111/2049-632X.12125 ] [PMID: 24376225]
[8]
Doi, Y.; Murray, G.L.; Peleg, A.Y. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin. Respir. Crit. Care Med., 2015, 36(1), 85-98.
[9]
Odsbu, I.; Khedkar, S.; Khedkar, U.; Nerkar, S.S.; Tamhankar, A.J.; Stålsby Lundborg, C. High proportions of multidrug-resistant Acinetobacter spp. isolates in a district in Western India: a four-year antibiotic susceptibility study of clinical isolates. Int. J. Environ. Res. Public Health, 2018, 15(1), 153.
[http://dx.doi.org/10.3390/ijerph15010153 ] [PMID: 29351187]
[10]
Vijayakumar, S.; Gopi, R.; Gunasekaran, P.; Bharathy, M.; Walia, K.; Anandan, S.; Veeraraghavan, B. Molecular characterization of invasive carbapenem-resistant Acinetobacter baumannii from a tertiary care hospital in South India. Infect. Dis. Ther., 2016, 5(3), 379-387.
[http://dx.doi.org/10.1007/s40121-016-0125-y ] [PMID: 27553951]
[11]
Obeidat, N.; Jawdat, F.; Al-Bakri, A.G.; Shehabi, A.A. Major biologic characteristics of Acinetobacter baumannii isolates from hospital environmental and patients’ respiratory tract sources. Am. J. Infect. Control, 2014, 42(4), 401-404.
[http://dx.doi.org/10.1016/j.ajic.2013.10.010 ] [PMID: 24679567]
[12]
Qouzah, H. F.; Hawari, F.; Abu-Qatouseh, L. F.; Shehabi, A. A. Occurrence and molecular characterization of metallo-β-lactamases (MBLs) among Acinetobacter baumannii isolates from cancer patients. Int. Arab. J. Antimicrob. Agents 2018, 8(2)
[13]
Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; Paterson, D.L.; Rice, L.B.; Stelling, J.; Struelens, M.J.; Vatopoulos, A.; Weber, J.T.; Monnet, D.L. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect., 2012, 18(3), 268-281.
[http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x ] [PMID: 21793988]
[14]
Sieniawski, K.; Kaczka, K.; Rucińska, M.; Gagis, L.; Pomorski, L. Acinetobacter baumannii nosocomial infections. Pol. Przegl. Chir., 2013, 85(9), 483-490.
[http://dx.doi.org/10.2478/pjs-2013-0075 ] [PMID: 24133105]
[15]
City population, Jordan. Available from: https://www.city population. de/ Jordan-Cities.html
[16]
Martín-Aspas, A.; Guerrero-Sánchez, F.M.; García-Colchero, F.; Rodríguez-Roca, S.; Girón-González, J-A. Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality. Infect. Drug Resist., 2018, 11, 861-872.
[http://dx.doi.org/10.2147/IDR.S163944 ] [PMID: 29922077]
[17]
El Emam, K.; Rodgers, S.; Malin, B. Anonymising and sharing individual patient data. BMJ, 2015, 350, h1139.
[http://dx.doi.org/10.1136/bmj.h1139 ] [PMID: 25794882]
[18]
Bauer, A.; Kirby, W.; Sherris, J. C.; Turck, M. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol, 1966, 45(4_ts), 493-496.
[http://dx.doi.org/10.1093/ajcp/45.4_ts.493 ]
[19]
Performance Standards for Antimicrobial Susceptibility Testing. 27th ed In: CLSI SUPPLEMENT M100; , 2017.
[20]
Antimicrobial Susceptibility Tests on Groups of Organisms or Agents for Which There Are No EUCAST Breakpoints 2016. Available from: http://Www.Eucast.Org/Guidance_Documents/
[21]
Ye, J.J.; Huang, C.T.; Shie, S.S.; Huang, P.Y.; Su, L.H.; Chiu, C.H.; Leu, H.S.; Chiang, P.C. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One, 2010, 5(4)e9947
[http://dx.doi.org/10.1371/journal.pone.0009947 ] [PMID: 20369056]
[22]
Jones, R.N.; Ferraro, M.J.; Reller, L.B.; Schreckenberger, P.C.; Swenson, J.M.; Sader, H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J. Clin. Microbiol., 2007, 45(1), 227-230.
[http://dx.doi.org/10.1128/JCM.01588-06 ] [PMID: 17093026]
[23]
Duin, V.D.; Paterson, D.L. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect. Dis. Clin. North Am., 2016, 30(2), 377-390.
[http://dx.doi.org/10.1016/j.idc.2016.02.004 ] [PMID: 27208764]
[24]
Ketter, P.M.; Guentzel, M.N.; Schaffer, B.; Herzig, M.; Wu, X.; Montgomery, R.K.; Parida, B.K.; Fedyk, C.G.; Yu, J-J.; Jorgensen, J.; Chambers, J.P.; Cap, A.P.; Arulanandam, B.P. Severe Acinetobacter baumannii sepsis is associated with elevation of pentraxin 3. Infect. Immun., 2014, 82(9), 3910-3918.
[http://dx.doi.org/10.1128/IAI.01958-14 ] [PMID: 25001601]
[25]
Batarseh, A.; Al-Sarhan, A.; Maayteh, M.; Al-Khatirei, S.; Alarmouti, M. Antibiogram of multidrug resistant Acinetobacter baumannii isolated from clinical specimens at King Hussein Medical Centre, Jordan: a retrospective analysis. East. Mediterr. Health J., 2016, 21(11), 828-834.
[http://dx.doi.org/10.26719/2015.21.11.828 ] [PMID: 26857720]
[26]
Shah, M.W.; Yasir, M.; Farman, M.; Jiman-Fatani, A.A.; Almasaudi, S.B.; Alawi, M.; El-Hossary, D.; Azhar, E.I. Antimicrobial Susceptibility and Molecular Characterization of Clinical Strains of Acinetobacter baumannii in Western Saudi Arabia. Microb. Drug Resist., 2019, 25(9), 1297-1305.
[http://dx.doi.org/10.1089/mdr.2019.0018]
[27]
Hussein, N.H.; Al-Mathkhury, H.J.F.; Sabbah, M.A. Imipenem-Resistant Acinetobacter baumannii isolated from patients and hospitals environment in Baghdad. Iraqi J. Sci., 2013, 54(4), 803-812.
[28]
Hamzeh, A.R.; Al Najjar, M.; Mahfoud, M. Prevalence of antibiotic resistance among Acinetobacter baumannii isolates from Aleppo, Syria. Am. J. Infect. Control, 2012, 40(8), 776-777.
[http://dx.doi.org/10.1016/j.ajic.2011.09.019 ] [PMID: 22305413]
[29]
Espinal, P.; Poirel, L.; Carmeli, Y.; Kaase, M.; Pal, T.; Nordmann, P.; Vila, J. Spread of NDM-2-producing Acinetobacter baumannii in the Middle East. J. Antimicrob. Chemother., 2013, 68(8), 1928-1930.
[http://dx.doi.org/10.1093/jac/dkt109 ] [PMID: 23674763]
[30]
Ali, H.M.; Salem, M.Z.M.; El-Shikh, M.S.; Megeed, A.A.; Alogaibi, Y.A.; Talea, I.A. Investigation of the virulence factors and molecular characterization of the clonal relations of multidrug-resistant Acinetobacter baumannii isolates. J. AOAC Int., 2017, 100(1), 152-158.
[http://dx.doi.org/10.5740/jaoacint.16-0139 ] [PMID: 27765082]
[31]
Jordan, National Action Plan to Combat Antimicrobial Resistance In Hashemite Kingdom of Jordan (2018-2022). Available from http://www.moh.gov.jo/EchoBusV3.0/SystemAssets/communicable/AMR%20plan.pdf
[32]
Isler, B.; Doi, Y.; Bonomo, R.A.; Paterson, D.L. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob. Agents Chemother., 2018, 63(1), e01110-e01118.
[http://dx.doi.org/10.1128/AAC.01110-18 ] [PMID: 30323035]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy